Researchers have developed an immune-independent bacterial therapy demonstrating complete tumor remission in both immunocompetent and immunocompromised mice, representing a revolutionary advance in cancer treatment applicable where immune function is compromised. Concurrently, studies illuminate histone lactylation’s role in immune resistance and reveal novel immune checkpoint targets such as TIGIT and mechanisms activating natural killer cells. These advances broaden the landscape for immuno-oncology therapeutics.